TNGX · NASDAQ · Biotechnology

Tango Therapeutics (TNGX)

Develops MTAP-selective PRMT5 inhibitors for genetically defined cancers.

$25.69
After hours+0.15 (+0.59%)
At close$25.54(+14.38%)